D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6
Paul J. Hesketh,Rogerio Lilenbaum,Kari Chansky,Afshin Dowlati,Patricia Graham,Robert Chapman,John Crowley,David R. Gandara +7 more
TL;DR: These chemotherapy regimens were associated with an encouraging disease-control rate (54%) in patients 80 years or older with advanced NSCLC, with good tolerance, and Selected octogenarians with advanced NCI may benefit from single-agent chemotherapy.
Journal ArticleDOI
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
David R. Gandara,Howard West,Kari Chansky,Angela M. Davies,Derick H Lau,John Crowley,Paul H. Gumerlock,Fred R. Hirsch,Wilbur A. Franklin +8 more
TL;DR: Clinical data and preliminary results of correlative science studies analyzing human epidermal growth factor receptor pathways from the following two prospective Southwest Oncology Group clinical trials performed in advanced stage BAC provide a biological rationale for investigating BAC as a model of predictive markers of EGFR inhibition.
Journal Article
RB Status as a Determinant of Response to UCN-01 in Non-Small Cell Lung Carcinoma
Philip C. Mack,David R. Gandara,Cai Bowen,Cai Bowen,Martin J. Edelman,Martin J. Edelman,Teresa Paglieroni,Joachim B. Schnier,Edward P. Gelmann,Edward P. Gelmann,Paul H. Gumerlock,Paul H. Gumerlock +11 more
TL;DR: It is concluded that UCN-01-induced G1 arrest can occur in cells null for p53 and p16CDKN2, and that RB status influences the ability of UCn-01 to induce a G1 arrests.
Journal ArticleDOI
Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819
TL;DR: A subgroup-focused, multiple-hypothesis design was selected for S0819 that incorporates coprimary endpoints to assess cetuximab in both the overall study population and among EGFR FISH-positive (FISH+) patients, with the sample size determined based on evaluation in the EG FR FISH+ group.
Journal ArticleDOI
Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation
Angela M. Davies,Cheryl Ho,Laurel A. Beckett,Laurel A. Beckett,Derick H Lau,Derick H Lau,Sidney A. Scudder,Sidney A. Scudder,Primo N. Lara,Primo N. Lara,Natasha Perkins,Natasha Perkins,David R. Gandara,David R. Gandara +13 more
TL;DR: This is the first clinical trial to test intermittent erlotinib plus pemetrexed and it is reported that this approach is feasible and well tolerated and arm B efficacy is being examined in a randomized phase II trial for second-line NSCLC.